Literature DB >> 17959859

Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis.

Fiona Murray1, Nikos Darzentas, Anastasia Hadzidimitriou, Gerard Tobin, Myriam Boudjogra, Cristina Scielzo, Nikolaos Laoutaris, Karin Karlsson, Fanny Baran-Marzsak, Athanasios Tsaftaris, Carol Moreno, Achilles Anagnostopoulos, Federico Caligaris-Cappio, Dominique Vaur, Christos Ouzounis, Chrysoula Belessi, Paolo Ghia, Fred Davi, Richard Rosenquist, Kostas Stamatopoulos.   

Abstract

Somatic hypermutation (SHM) features in a series of 1967 immunoglobulin heavy chain gene (IGH) rearrangements obtained from patients with chronic lymphocytic leukemia (CLL) were examined and compared with IGH sequences from non-CLL B cells available in public databases. SHM analysis was performed for all 1290 CLL sequences in this cohort with less than 100% identity to germ line. At the cohort level, SHM patterns were typical of a canonical SHM process. However, important differences emerged from the analysis of certain subgroups of CLL sequences defined by: (1) IGHV gene usage, (2) presence of stereotyped heavy chain complementarity-determining region 3 (HCDR3) sequences, and (3) mutational load. Recurrent, "stereotyped" amino acid changes occurred across the entire IGHV region in CLL subsets carrying stereotyped HCDR3 sequences, especially those expressing the IGHV3-21 and IGHV4-34 genes. These mutations are underrepresented among non-CLL sequences and thus can be considered as CLL-biased. Furthermore, it was shown that even a low level of mutations may be functionally relevant, given that stereotyped amino acid changes can be found in subsets of minimally mutated cases. The precise targeting and distinctive features of somatic hypermutation (SHM) in selected subgroups of CLL patients provide further evidence for selection by specific antigenic element(s).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17959859     DOI: 10.1182/blood-2007-07-099564

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  96 in total

1.  Enhanced outgrowth of EBV-transformed chronic lymphocytic leukemia B cells mediated by coculture with macrophage feeder cells.

Authors:  Kwan-Ki Hwang; Xi Chen; Daniel M Kozink; Marietta Gustilo; Dawn J Marshall; John F Whitesides; Hua-Xin Liao; Rosa Catera; Charles C Chu; Xiao-Jie Yan; Micah A Luftig; Barton F Haynes; Nicholas Chiorazzi
Journal:  Blood       Date:  2011-12-12       Impact factor: 22.113

2.  Distinct gene expression profiles in subsets of chronic lymphocytic leukemia expressing stereotyped IGHV4-34 B-cell receptors.

Authors:  Millaray Marincevic; Mahmoud Mansouri; Meena Kanduri; Anders Isaksson; Hanna Göransson; Karin Ekström Smedby; Jesper Jurlander; Gunnar Juliusson; Fred Davi; Kostas Stamatopoulos; Richard Rosenquist
Journal:  Haematologica       Date:  2010-08-26       Impact factor: 9.941

3.  High-density screening reveals a different spectrum of genomic aberrations in chronic lymphocytic leukemia patients with 'stereotyped' IGHV3-21 and IGHV4-34 B-cell receptors.

Authors:  Millaray Marincevic; Nicola Cahill; Rebeqa Gunnarsson; Anders Isaksson; Mahmoud Mansouri; Hanna Göransson; Markus Rasmussen; Mattias Jansson; Fergus Ryan; Karin Karlsson; Hans-Olov Adami; Fred Davi; Jesper Jurlander; Gunnar Juliusson; Kostas Stamatopoulos; Richard Rosenquist
Journal:  Haematologica       Date:  2010-04-26       Impact factor: 9.941

4.  Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma.

Authors:  Silvia Zibellini; Daniela Capello; Francesco Forconi; Paolo Marcatili; Davide Rossi; Sara Rattotti; Silvia Franceschetti; Elisa Sozzi; Emanuele Cencini; Roberto Marasca; Luca Baldini; Alessandra Tucci; Francesco Bertoni; Francesco Passamonti; Ester Orlandi; Marzia Varettoni; Michele Merli; Silvia Rizzi; Valter Gattei; Anna Tramontano; Marco Paulli; Gianluca Gaidano; Luca Arcaini
Journal:  Haematologica       Date:  2010-05-29       Impact factor: 9.941

5.  Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation.

Authors:  David Oscier; Rachel Wade; Zadie Davis; Alison Morilla; Giles Best; Sue Richards; Monica Else; Estella Matutes; Daniel Catovsky
Journal:  Haematologica       Date:  2010-05-29       Impact factor: 9.941

Review 6.  Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities.

Authors:  Nicholas Chiorazzi; Manlio Ferrarini
Journal:  Blood       Date:  2010-12-09       Impact factor: 22.113

7.  Biological and clinical significance of stereotyped B-cell receptors in chronic lymphocytic leukemia.

Authors:  Davide Rossi; Gianluca Gaidano
Journal:  Haematologica       Date:  2010-12       Impact factor: 9.941

8.  Torque teno virus 10 isolated by genome amplification techniques from a patient with concomitant chronic lymphocytic leukemia and polycythemia vera.

Authors:  Charles C Chu; Lu Zhang; Arjun Dhayalan; Briana M Agagnina; Amanda R Magli; Gia Fraher; Sebastien Didier; Linda P Johnson; William J Kennedy; Rajendra N Damle; Xiao-Jie Yan; Piers E M Patten; Saul Teichberg; Prasad Koduru; Jonathan E Kolitz; Steven L Allen; Kanti R Rai; Nicholas Chiorazzi
Journal:  Mol Med       Date:  2011-09-21       Impact factor: 6.354

9.  Genetic landscape of hepatitis B virus-associated diffuse large B-cell lymphoma.

Authors:  Weicheng Ren; Xiaofei Ye; Hong Su; Wei Li; Dongbing Liu; Mohammad Pirmoradian; Xianhuo Wang; Bo Zhang; Qiang Zhang; Longyun Chen; Man Nie; Yao Liu; Bin Meng; Huiqiang Huang; Wenqi Jiang; Yixin Zeng; Wenyu Li; Kui Wu; Yong Hou; Klas G Wiman; Zhiming Li; Huilai Zhang; Roujun Peng; Shida Zhu; Qiang Pan-Hammarström
Journal:  Blood       Date:  2018-03-15       Impact factor: 22.113

10.  An entity evolving into a community: defining the common ancestor and evolutionary trajectory of chronic lymphocytic leukemia stereotyped subset #4.

Authors:  Lesley-Ann Sutton; Giorgos Papadopoulos; Anastasia Hadzidimitriou; Stavros Papadopoulos; Efterpi Kostareli; Richard Rosenquist; Dimitrios Tzovaras; Kostas Stamatopoulos
Journal:  Mol Med       Date:  2015-04-02       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.